Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases.
anti‐interleukin‐12/23
efficacy
persistence
safety
Journal
JGH open : an open access journal of gastroenterology and hepatology
ISSN: 2397-9070
Titre abrégé: JGH Open
Pays: Australia
ID NLM: 101730833
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
08
01
2021
accepted:
13
01
2021
entrez:
18
3
2021
pubmed:
19
3
2021
medline:
19
3
2021
Statut:
epublish
Résumé
Ustekinumab is approved in Europe for the treatment of moderate to severe Crohn's disease (CD). Italian real-life data are scarce, so the aim of this study was to assess the effectiveness and safety of ustekinumab in an Italian cohort of CD patients. Data of patients with CD who started using ustekinumab were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Disease. Primary end-points were steroid-free clinical remission at 8, 24, and 52 weeks of therapy and reduction of C-reactive protein. Secondary end-points were treatment response, treatment persistence at 12 months, and safety. A total of 131 patients (males 56%; mean age 46 years Data from our real-life cohort of treatment-refractory CD patients suggest the satisfactory effectiveness and safety profile of ustekinumab.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Ustekinumab is approved in Europe for the treatment of moderate to severe Crohn's disease (CD). Italian real-life data are scarce, so the aim of this study was to assess the effectiveness and safety of ustekinumab in an Italian cohort of CD patients.
METHODS
METHODS
Data of patients with CD who started using ustekinumab were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Disease. Primary end-points were steroid-free clinical remission at 8, 24, and 52 weeks of therapy and reduction of C-reactive protein. Secondary end-points were treatment response, treatment persistence at 12 months, and safety.
RESULTS
RESULTS
A total of 131 patients (males 56%; mean age 46 years
CONCLUSIONS
CONCLUSIONS
Data from our real-life cohort of treatment-refractory CD patients suggest the satisfactory effectiveness and safety profile of ustekinumab.
Identifiants
pubmed: 33732883
doi: 10.1002/jgh3.12502
pii: JGH312502
pmc: PMC7936616
doi:
Types de publication
Journal Article
Langues
eng
Pagination
364-370Informations de copyright
© 2021 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Aliment Pharmacol Ther. 2020 May;51(10):948-957
pubmed: 32249966
N Engl J Med. 2016 Nov 17;375(20):1946-1960
pubmed: 27959607
J Clin Med. 2019 Dec 04;8(12):
pubmed: 31817134
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
J Crohns Colitis. 2019 Oct 28;13(11):1401-1409
pubmed: 30989232
Can J Gastroenterol. 2005 Sep;19 Suppl A:5A-36A
pubmed: 16151544
Lancet. 2002 May 4;359(9317):1541-9
pubmed: 12047962
N Engl J Med. 2012 Oct 18;367(16):1519-28
pubmed: 23075178
Gastroenterol Hepatol. 2020 Mar;43(3):126-132
pubmed: 31866167
Frontline Gastroenterol. 2019 May 29;11(2):111-116
pubmed: 32133109
Drugs Aging. 2020 May;37(5):383-392
pubmed: 32016824
Gastroenterology. 2008 Oct;135(4):1130-41
pubmed: 18706417
Eur J Gastroenterol Hepatol. 2020 Dec;32(12):1507-1513
pubmed: 32868649
J Crohns Colitis. 2020 Jan 1;14(1):33-45
pubmed: 31219157
World J Gastroenterol. 2019 Aug 21;25(31):4481-4492
pubmed: 31496626
J Crohns Colitis. 2019 Jul 25;13(7):864-872
pubmed: 30715258
N Engl J Med. 2013 Aug 22;369(8):711-21
pubmed: 23964933
Therap Adv Gastroenterol. 2016 Jan;9(1):26-36
pubmed: 26770265
United European Gastroenterol J. 2020 May;8(4):418-424
pubmed: 32213026
Expert Opin Biol Ther. 2020 Feb;20(2):193-203
pubmed: 31859538
Adv Ther. 2020 May;37(5):2127-2143
pubmed: 32193810